Covid-19 living Data

COVID-19 vaccine effectiveness
(Randomized evidence)

Analyses are updated every Friday

Variants of concern

Treatment comparisons

Trials reports under extraction

In addition to the below included trials, we have included and presently extracting 6 new vaccine randomized trials:

Hsieha SM, EClinicalMedicine, 2021	Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
Low JG, medRxiv, 2021	A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults
Meng FY, SIGNAL TRANSDUCT TAR, 2021	Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.
Nguyen T, medRxiv, 2021	Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein Vaccine
Wanshen G, EclinicalMedicine, 2021	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
Wu S, Lancet Infect Dis, 2021	Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Description of primary studies

In this table, we report the main characteristics of the COVID-19 vaccine candidates from RCTs identified. The presented data is preliminary and ROB assessment is still under quality control. Please contact us if you notice an inaccuracy.

Risk of bias appears in black for some studies because the assessment data is not available to proceed with the assessment. Non randomized studies are not included in the table.

For phase 1-2 studies, we report on the general charecteristics and assess the risk of Bias for safety outcomes only. Results from phase1-2 studies are included in forest plots for the chosen vaccine dose and schedule.

The evidence synthesis with forest plots and summary of findings table and evidence profile are provided for the chosen vaccine schedule with results collected from relevant phase 1, 2 and 3 studies.

Results for each vaccine comparisons are the summary of evidence from the latest study report results.

Trial	Type	Comparisons		Design	Participants	Sample size	Overall risk of bias Highest assessment	Full description
		Intervention 1	Intervention 2
NCT04510207, ChiCTR2000034780 Sinopharm - China National Biotec Group Company Limited Al Kaabi N, JAMA, 2021 Full text Commentary Commentary	Inactivated virus	WIV04 HBO2	Placebo	RCT Phase 3	Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain	N=40411	Some concerns Details	Full description
NCT04470427 ModernaTX Baden LR, N Engl J Med, 2020 COVE Full text Commentary	RNA based vaccine	mRNA-1273	Placebo	RCT Phase 3	Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US	N=30420	Some concerns Details	Full description
NCT04860739, EudraCT2021-001978-37 Pfizer/BioNTech + Fosun Pharma Borobia A M, Lancet, 2021 Full text Commentary	RNA based vaccine	BNT162b2	No vaccine	RCT Phase 2	Healthy, or clinically stable, adults (aged ≥18 and ≤60) that were SARS-COV-2 infection free and who had received a prime ChAdOx1-S vaccination between 8 and 12 weeks before the screening visit in 5 centers in Spain.	N=676	Some concerns Details	Full description
NCT04651790 Sinovac Research and Development Co., Ltd Bueno S, medRxiv, 2021 Full text Commentary Commentary	Inactivated virus	CoronaVac	Placebo	RCT Phase 3	Adult healthcare workers with no history of confirmed symptomatic SARS-CoV-2 infection who were in contact with possible or confirmed cases of COVID-19 in 8 sites in Chile.	N=434	Low Details	Full description
NCT04495933 The University of Queensland; Syneos Health; CSIRO Manufacturing; Seqirus; Coalition for Epidemic Preparedness Innovations Chappell K, Lancet, 2021 Full text Commentary	Protein subunit	SARS-CoV-2 Sclamp 5-mcg D SARS-CoV-2 Sclamp 15-mcg SARS-CoV-2 Sclamp 45-mcg SARS-CoV-2 Sclamp 45-mcg	Placebo D0/28	RCT Phase 1	Healthy SARS-CoV-2 infection-free adults aged 18-55 at one center in Australia.	N=120	Some concerns Details	Full description
NCT04412538 Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAMS). Che Y, Clin Infect Dis, 2020 Full text Commentary	Inactivated virus	KMS-1 100 EU D0/14 KMS-1 150 EU D0/14 KMS-1 100 EU D0/28 KMS-1 150 EU D0/28	Adjuvant D0/14	RCT Phase 2	Healthy SARS-CoV-2 serology/DNA negative adults in two centres in China	N=750	Some concerns Details	Full description
NCT04641481 Bharat Biotech Ella R, medRxiv, 2021 New Full text Commentary Commentary	Inactivated virus	BBV152	Placebo	RCT 3	Adults with no history of SARS-CoV-2 infection who were healthy or had stable chronic medical conditions at 25 centers in India	N=25778	Some concerns Details	Full description
NCT04471519 ; CTRI/2 Bharat Biotech Ella R, Lancet Infect Dis, 2021 Full text Commentary ; Commentary	Inactivated virus	6mcg BBV152 + Algel-IMDG	3mcg BBV152 + Algel-IMDG	RCT Phase 2	Healthy adults (<65 yo) and children (≥12 yo)volunteers, SARS-CoV-2 infection-free in 9 centres in India	N=380	Some concerns Details	Full description
NCT04471519 ; CTRI/2 Bharat Biotech Ella R, Lancet Infect Dis, 2021 Full text Commentary	Inactivated virus	BBV152 3mcg + Algel-IMDG BBV152 6mcg + Algel-IMDG BBV152 6mcg + Algel D0/1	Adjuvant D0/14	RCT Phase 1	Healthy SARS-CoV-2 serology/PCR negative adults in 11 centres in India	N=375	Low Details	Full description
NCT04400838 AstraZeneca + University of Oxford Emary K, Lancet, 2021 Full text Commentary	Non replicating viral vector	ChAdOx1	MenACWY	RCT Phase 2-3	Adults seronegative at baseline enrolled at 19 study sites in UK	N=10673	Some concerns Details	Full description
NCT04324606; ISRCTN1 University of Oxford/AstraZeneca Folegatti PM, Lancet, 2020 COV001 Full text Commentary ; Commentary (20)31611-1/fulltext	Non replicating viral vector	ChAdOx1 SD	MenACWY	RCT Phase 1 - 2	Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK	N=1067	Low Details	Full description
NCT04368988 Novavax Formica N, medRxiv, 2021 Full text Commentary Commentary	Protein subunit	NVX-CoV2373 NVX-CoV2373 5mcg D0 25mcg NVX-CoV2373 D0/D21 25mcg NVX-CoV2373 D0	Placebo	RCT Phase 2	Healthy adults (stable comorbidities and confirmed COVID-19 with mild symptoms permitted) aged 18-84 years at 17 centers in Australia and USA	N=1288	Some concerns Details	Full description
NCT04368728 Pfizer/BioNTech + Fosun Pharma Frenck R, N Engl J Med, 2021 Full text Commentary	RNA based vaccine	BNT162b2	Placebo	RCT Phase 3	Adolescents aged 12 to 15 years with no previous Covid-19 diagnosis or SARS-CoV-2 infection in 29 centers in the USA	N=2264	Some concerns Details	Full description
NCT04636697 Medicago Inc Gobeil P, medRxiv, 2021 Full text Commentary Commentary	Virus-Like particle (VLP)	CoVLP 3.75mcg +AS03	Placebo	RCT Phase 2	Healthy adults and non-institutionalized older adults (seronegative and seropositive) in multiple centers in Canada and the USA	N=588	N/A	Full description
NCT04537208 Sanofi Pasteur, GlaxoSmithKline Goepfert P, Lancet, 2021 Full text Commentary	Protein subunit	CoV2 preS dTM LD + AFO3 CoV2 preS dTM LD + ASO3 CoV2 preS dTM HD + AFO3 CoV2 preS dTM HD + ASO3 CoV2 preS dTM HD	Placebo	RCT Phase 1-2	Health adults aged 18 years and older and SARS-CoV-2 infection-free in 10 centres in the USA.	N=271	Some concerns Details	Full description
NCT04551547 Sinovac Research and Development Co., Ltd Han B, SSRN, 2021 Full text Commentary Commentary	Inactivated virus	CoronaVac 1.5 mcg D0/28 Adjuvant D0/28	CoronaVac 3.0 mcg D0/28	RCT Phase 1/2	Healthy children and adolescents aged 3-17 years with no history of SARS-CoV-2 infection in a single centre in China.	N=552	Low Details	Full description
NCT04583995; EudraCT 2020-004123-16 Novavax Heath P, N Engl J Med, 2021 Full text Commentary	Protein subunit	NVX-CoV2373	Placebo	RCT Phase 3	Adults 18 to 84 years old who were healthy or had stable chronic medical conditions with no history of COVID-19 at 33 centres in the UK.	N=15187	Some concerns Details	Full description
NCT04368988 Novavax Keech C, N Engl J Med, 2020 Full text Commentary	Protein subunit	25mcg NVX-D0/21 NVX-CoV2373 25mcg NVX/M1-D0/21 25mcg NVX/M1+Placebo-D0/2	Placebo	RCT Phase 1	Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia.	N=134	Some concerns Details	Full description
ChiCTR2000034825 ; NCT04523571 BioNTech RNA Pharmaceuticals Li J, Nature Medicine, 2021 Full text Commentary	RNA based vaccine	BNT162b1 10 mcg	BNT162b1 10 mcg	RCT Phase 1	Healthy young adults between 18 and 55 years of age, and older adults between 65 and 85 that were SARS-COVID-2 infection-free at a single center in China.	N=144	Low Details	Full description
ChiCTR2100045108 Guangdong Provincial Center for Disease Control and Prevention Liao Y, Emerg Microbes Infec, 2021 New Full text Commentary	Protein subunit	V-01 10 mcg V-01 25 mcg V-01 50 mcg	Adjuvant	RCT Phase 1	Healthy seronegative adults with no history of COVID-19 in a single center in China	N=180	Some concerns Details	Full description
ISRCTN69254139, EudraCT: 2020-005085-33 AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma Liu X, SSRN, 2021 Com-COV Full text Commentary Commentary Commentary Commentary	RNA based vaccine	ChAd/ChAd-28 BNT/BNT-28	ChAd/BNT-28 BNT/ChAd-28	RCT Phase 2	Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK	N=463	Some concerns Details	Full description
NCT04530396 Gamaleya Research Institute of Epidemiology and Microbiology Logunov D, Lancet, 2021 RESIST Full text Commentary ; Commentary ; Commentary	Non replicating viral vector	GAM-COVID-VAC	Placebo	RCT Phase 3	SARS-CoV-2- and HIV infection-free adult volunteers at 25 centers in Russia	N=21977	Some concerns Details	Full description
NCT04444674 University of Oxford/AstraZeneca Madhi S, N Engl J Med, 2021 COV005 Full text Commentary	Non replicating viral vector	ChAdOx1	Placebo	RCT Phase 1-2	Healthy adult volunteers that were HIV-negative and SARS-CoV-2 infection-free in 7 centres in South Africa	N=2026	Some concerns Details	Full description
NCT04444674, PACTR202006922165132 AstraZeneca + University of Oxford Madhi S, Research square , 2021 Full text Commentary	Non replicating viral vector	ChAdOx1 nCoV-19	Placebo D0/28	RCT Phase 1-2	Adults living with HIV in 7 centers in South Africa	N=104	Some concerns Details	Full description
NCT04642638 Inovio Pharmaceuticals Mammen Jr M, medRxiv, 2021 Full text Commentary Commentary	DNA based vaccine	INO-4800 1mg D0/28 INO-4800 2mg D0/28	Placebo 1 D0/28 Placebo 2 D0/28	RCT Phase 2	Healthy adult volunteers SARS-CoV-2 seronegative at high risk of infection at 16 locations in the USA.	N=201	Some concerns Details	Full description
NCT04456595 Sinovac Research and Development Co., Ltd Palacios R, SSRN, 2021 PROFISCOV Full text Commentary	Inactivated virus	CoronaVac	Placebo	RCT Phase 3	Healthcare professionals with or without previous COVID-19 infection caring for COVID-19 patients at 16 centers in Brazil.	N=12408	Some concerns Details	Full description
NCT04758273, ChiCTR2000038804 Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Pan HX, Chin Med J, 2021 Full text Commentary	Inactivated virus	5mcg KCONVAC	10mcg KCONVAC	RCT Phase 1	Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China.	N=60	Low Details	Full description
NCT04756323, ChiCTR2000039462 Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Pan HX, Chin Med J, 2021 Full text Commentary	Inactivated virus	KCONVAC 5mcg D0/14 KCONVAC 5mcg D0/14 KCONVAC 5mcg D0/28 KCONVAC 5mcg D0/28 KCONVAC 5mcg D0/14 KCONVAC 10mcg D0/14	KCONVAC 10mcg D0/14 KCONVAC 5mcg D0/14 KCONVAC 10mcg D0/28 Placebo D0/28 Placebo D0/14 Placebo D0/14	RCT Phase 2	Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China.	N=500	Low Details	Full description
NCT04368728 Pfizer/BioNTech + Fosun Pharma Polack F, N Engl J Med, 2020 Full text Commentary ; Commentary ; Commentary ; Commentary ; Commentary	RNA based vaccine	BNT162b2	Placebo	RCT Phase 2/3	Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA	N=43448	Some concerns Details	Full description
NCT04412538 The Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAM Pu J, Vaccine, 2021 Full text Commentary	Inactivated virus	KMS-1 100 EU D0/14 KMS-1 100 EU D0/28	Placebo D0/14	RCT Phase 1	Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China	N=192	Some concerns Details	Full description
NCT04405908 Clover Biopharmaceuticals, Chengdu, China Richmond P, Lancet, 2021 Full text Commentary	Protein subunit	SCB-2019 3 mcg SCB-2019 3 mcg + AS03 SCB-2019 3 mcg + CpG/Alum SCB-2019 9 mcg SCB-2019 9 mcg + AS03 SCB-2019 9 mcg + CpG/Alum SCB-2019 30 mcg SCB-2019 30 mcg + AS03 SCB-2019 30 mcg + CpG/Alu	Placebo	RCT Phase 1	Healthy SARS-CoV-2 serology/DNA negative adults aged 18-75 years at one study center in Australia	N=151	Low Details	Full description
NCT04527575 EpiVac LLC ; State Scientific Center of Virology and Biotechnology “Vector” of Rospotrebnadzor Ryzhikov AB, Infektsiia Immun, 2021 Full text Commentary	Protein subunit	EpiVacCorona	Placebo	RCT Phase 2	Healthy adult SARS-CoV-2 infection-free volunteers in a single center in Russia.	N=86	Some concerns Details	Full description
NCT04436276 Janssen Pharmaceutical Companies Sadoff J, N Engl J Med, 2021 ENSEMBLE Full text Commentary	Non replicating viral vector	Ad26.COV2.S 5x10^10vp Ad26.COV2.S 1x10^11vp	Placebo	RCT Phase 1-2	Healthy SARS-CoV-2 nucleic acid negative adults 18-55 years old and elderly >65 years old in multiple centres in Belgium and the US	N=810	Some concerns Details	Full description
NCT04505722 Janssen Pharmaceutical Companies Sadoff J, N Engl J Med, 2021 ENSEMBLE Full text Commentary	Non replicating viral vector	Ad26.COV2.S	Placebo	RCT Phase 3	Adults >18 years of age at 213 centers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and USA	N=44325	Some concerns Details	Full description
NCT04533399; PACTR202009726132275 Novavax Shinde V, N Engl J Med, 2021 Full text Commentary	Protein subunit	NVX-CoV2373	Placebo	RCT Phase 2a/b	HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa	N=4406	Some concerns Details	Full description
NCT04582344 Sinovac Research and Development Co., Ltd Tanriover M, Lancet , 2021 Full text Commentary Commentary	Inactivated virus	CoronaVac	Adjuvant	RCT Phase 3	Healthy healthcare workers and adults aged 18–59 years with no history of COVID-19 from 24 centres in Turkey	N=10218	Some concerns Details	Full description
ISRCTN89951424 University of Oxford/AstraZeneca Voysey M, Lancet, 2020 COV003 Full text Commentary	Non replicating viral vector	ChAdOx1 SD/SD	MenACWY/saline	RCT Phase 3	Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil	N=10002	Some concerns Details	Full description
NCT04324606 / EudraC AstraZeneca + University of Oxford Voysey M, Lancet, 2021 COV001/COV002/COV003/COV005 Full text Commentary ; Commentary ; Commentary	Non replicating viral vector	ChAdOx1	MenACWY/saline	RCT phase 1/2/3	Adults seronegative at baseline from four studies in multiple centres in Brazil, South Africa, and the UK	N=24422	Some concerns Details	Full description
NCT04400838 University of Oxford/AstraZeneca Voysey M, Lancet, 2020 COV002 Full text Commentary	Non replicating viral vector	ChAdOx1 LD/SD ChAdOx1 SD/SD	MenACWY	RCT Phase 2/3	Healthy adults in 18 centres in the UK	N=10673	Some concerns Details	Full description
NCT04368728 BioNTech SE, Pfizer Walsh E, N Engl J Med, 2020 Full text Commentary	RNA based vaccine	BNT162b1 10 mcg D1/21 BNT162b1 20 mcg D1/21 BNT162b1 30 mcg D1/21 BNT162b1 100 mcg D1/21 BNT162b2 10 mcg D1/21 BNT162b2 20 mcg D1/21 BNT162b2 30 mcg D1/21	BNT162b1 30 mcg D1/21	RCT Phase 1	Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA	N=195	Low Details	Full description
NCT04450004 Medicago Ward B, medRxiv, 2020 Full text Commentary ; Commentary	Virus-Like particle (VLP)	CoVLP 3.75mcg + CpG1018 CoVLP 3.75mcg + AS03 CoVLP 7.5mcg + CpG1018 CoVLP 7.5mcg + AS03 CoVLP 15mcg + CpG1018 CoVLP 15mcg + AS03	CoVLP 3.75mcg CoVLP 3.75mcg CoVLP 7.5mcg CoVLP 7.5mcg CoVLP 15mcg CoVLP 15mcg	RCT Phase 1	Healthy SARS-CoV-2 infection-free adults aged 18-55 years at 2 centers in Canada	N=180	Some concerns Details	Full description
NCT04383574 Sinovac Research and Development Co., Ltd Wu Z, Lancet Infect Dis, 2021 Full text Commentary ; Commentary	Inactivated virus	CoronaVac 1.5mcg D0/28 CoronaVac CoronaVac 6mcg D0/28	Adjuvant	RCT Phase 1/2	Healthy adults aged 60 years and older with no history of SARS-CoV-2 infection in a single centre in China	N=422	Low Details	Full description
ChiCTR2000031809 Wuhan Institute of Biological Products Co Ltd./Sinopharm Xia S, JAMA, 2020 Full text Commentary	Inactivated virus	Inactivated 2.5mcg-3doses Inactivated 5mcg-3doses Inactivated 10mcg-3doses Inactivated 5mcg-D0/14 Inactivated 5mcg-D0/21	Adjuvant	RCT Phase 1	Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test	N=320	Low Details	Full description
ChiCTR2000032459 Beijing Institute of Biological Products/Sinopharm Xia S, Lancet Infect Dis, 2020 Full text Commentary	Inactivated virus	BBIBP-CorV 8mcg once BBIBP-CorV 4mcg D0/14 BBIBP-CorV 4mcg D0/21 BBIBP-CorV 4mcg D0/28	Adjuvant	RCT Phase 2	Healthy SARS-CoV-2 serology negative adults 18-59 years old and ≥60 years old in a single centre in China	N=448	Some concerns Details	Full description
NCT04445194 Institute of Microbiology, Chinese Academy of Sciences ; Anhui Zhifei Longcom Biopharmaceutical Co., Ltd Yang S, Lancet, 2021 Full text Commentary	Protein subunit	ZF2001 25 mcg 3 doses ZF2001 50 mcg 3 doses	Adjuvant	RCT Phase 1	Healthy SARS-CoV-2 infection-free adults aged 18-59 at 2 centers in China	N=50	Some concerns Details	Full description
NCT04466085 Institute of Microbiology, Chinese Academy of Sciences ; Anhui Zhifei Longcom Biopharmaceutical Co., Ltd Yang S, Lancet, 2021 Full text Commentary	Protein subunit	ZF2001 25 mcg 2 doses ZF2001 50 mcg 2 doses ZF2001 25 mcg 3 doses ZF2001 50 mcg 3 doses	Adjuvant	RCT Phase 2	Healthy SARS-CoV-2 infection-free adults aged 18-59 at 1 center in China	N=900	Low Details	Full description
NCT04352608 Sinovac Research and Development Co., Ltd Zhang Y, Lancet Infect Dis, 2020 Full text Commentary ; Commentary	Inactivated virus	CoronaVac 6 mcg D0/28 CoronaVac 3 mcg D0/28 CoronaVac 6 mcg D0/14 CoronaVac	Adjuvant	RCT Phase 1	Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China	N=144	Some concerns Details	Full description
NCT04352608 Sinovac Research and Development Co., Ltd Zhang Y, Lancet Infect Dis, 2020 Full text Commentary ; Commentary	Inactivated virus	CoronaVac CoronaVac 6 mcg D0/14 CoronaVac 3 mcg D0/28 CoronaVac 6 mcg D0/28	Adjuvant	RCT Phase 2	Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China	N=600	Some concerns Details	Full description
NCT04341389 CanSino Biological Inc./Beijing Institute of Biotechnology Zhu F, Lancet, 2020 Full text Commentary Commentary	Non replicating viral vector	Ad5-vectored 1×10¹¹ vp Ad5-vectored 1×10¹¹ vp Ad5-vectored 5×10¹⁰ vp	Ad5-vectored 5×10¹⁰ vp Placebo Placebo	RCT Phase 2	Healthy adult volunteers with HIV-negative and SARS-CoV-2 infection-free in a single centre in China.	N=508	Some concerns Details	Full description
NCT04523571 ; ChiCTR BioNTech / Pfizer / Fosun Pharma Zhu F, ResearchSquare, 2021 Full text Commentary ; Commentary	RNA based vaccine	BNT126b1 10 mcg/0.5 ml 2- BNT126b1 30 mcg/0.5 ml 2-	Placebo	RCT Phase 1	Healthy SARS-CoV-2 infection-free adults aged 18-55 and 65-85 at a single center in China	N=144	Some concerns Details	Full description

COVID-19 vaccine effectiveness(Randomized evidence)

Variants of concern

Treatment comparisons

Trials reports under extraction

Description of primary studies

COVID-19 vaccine effectiveness
(Randomized evidence)